NNVCHIGH SIGNALFINANCIAL10-K

NNVC's cash position collapsed 67.5% to $1.6M while operating losses increased 34.3%, creating severe liquidity concerns despite advancing their lead drug to Phase II readiness.

The dramatic cash burn combined with widening losses puts the company in a precarious financial position that likely necessitates immediate fundraising to continue operations. While the clinical progress represents positive operational momentum, the severe deterioration in financial metrics raises going concern questions and potential dilution risks for existing shareholders.

Comparing 2025-09-29 vs 2024-09-27View on EDGAR →
FINANCIAL ANALYSIS

NNVC experienced severe financial deterioration with cash plummeting from $4.8M to $1.6M (-67.5%) and operating cash flow worsening from -$6.3M to -$8.5M (-34.3%), while net losses increased to -$9.5M. Total assets declined 31.2% and stockholders' equity dropped 34.4%, reflecting the company's rapidly depleting resources. The dramatic cash burn rate against minimal remaining liquidity signals an urgent need for external financing to sustain operations and clinical development programs.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-81.7%
$5K938

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-67.5%
$4.8M$1.6M

Cash declined 67.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-66.4%
$5.0M$1.7M

Current assets declined 66.4% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-63.6%
$157K$57K

Capex reduced 63.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-34.4%
$11.5M$7.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-34.3%
-$6.3M-$8.5M

Operating cash flow fell 34.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
-31.2%
$12.8M$8.8M

Total assets contracted 31.2% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
-14.1%
-$8.3M-$9.5M

Net income declined 14.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-12.6%
-$8.5M-$9.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2025-09-29
PRIOR — 2024-09-27
ADDED
We are a clinical stage company with our first drug ready to enter Phase II human clinical efficacy trial, having successfully completed Phase Ia/Ib human clinical safety and tolerability trial.
Based on our nanoviricides platform technology, we also have several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies.
We are engaged in developing a class of drugs, that we call nanoviricides , using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases.
This approach enables rapid development of effective new drugs against a number of different viruses, that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses.
The virus evolution is known to generate viruses that escape the traditional antiviral approaches vaccines, antibodies and small chemical drugs.
+7 more — sign up free →
REMOVED
We are a clinical stage company with our first drug in Phase Ia/Ib clinical trial and several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies.
We are engaged in the application of nanomedicine technologies to the complex issues of viral diseases.
We are developing a class of drugs, that we call nanoviricides , using a platform technology.
This approach enables rapid development of effective new drugs against a number of different viruses.
After decades of development, this novel nanoviricide technology has now successfully reached clinical stage.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →